cas 876343-10-1|| where to buy 4-chloro-6-iodo-7H-pyrrolo[2,3-d]pyrimidine

Nombre del producto:4-chloro-6-iodo-7H-pyrrolo[2,3-d]pyrimidine

IUPAC Name:4-chloro-6-iodo-7H-pyrrolo[2,3-d]pyrimidine

Unidad de embalaje	Stock disponible	Precio($)
CM104043-5g	in stock	ĳƚǟ
CM104043-10g	in stock	ƴƈħ
CM104043-25g	in stock	ƚƈǟ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 876343-10-1 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :876343-10-1; Fórmula molecular:C6H3ClIN3; Punto de fusión:-; Código de sonrisas:ClC1=C2C=C(I)NC2=NC=N1; Densidad:

: Número de catálogo:CM104043; Peso molecular:279.47; Punto de ebullición:; Nº Mdl:MFCD11518919; Almacenamiento:-20°C

: Pyrrolopyrimidines; Fusion heterocyclic compounds have various biological activities, such as anticancer, antibacterial, antifungal and anti-inflammatory, and thus have been widely used in the field of medicinal chemistry. Pyrrolopyrimidines are a major class of fused heterocyclic compounds. Compared with single pyrrole and pyrimidine cores, pyrrolopyrimidines have more diverse and effective pharmacological characteristics as fusion scaffolds.

: BMF-219; Biomea Fusion’s BMF-219 demonstrates promising early signs of clinical activity, with its ability to achieve durable and sustained complete responses (CRs) and minimal residual disease negativity (MRD-neg) in patients with acute myeloid leukemia (AML). Biomea Fusion recently presents this First Complete Responder from Ongoing Phase I Study at the 2023 ASH.
BMF-219 is the first and only covalent menin inhibitor in clinical development for AML, ALL, DLBCL, MM and CLL. Additionally, BMF-219 is being explored for its potential to regenerate insulin-producing beta cells as a treatment of type 1 diabetes.